<DOC>
	<DOCNO>NCT02350777</DOCNO>
	<brief_summary>The purpose study see give patient stem cell original donor ( boost ) remove T cell ( T cell depleted- TCD boost ) without chemotherapy . The investigator want see improve bone marrow function . This would also improve patient white blood count , red blood count platelet . This may make patient chance improve survive well . The investigator also look short term side effect risk TCD boost .</brief_summary>
	<brief_title>T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<criteria>Patients diagnose PGF candidate trial . Patients underwent transplant another facility suffer PGF eligible well long donor available . PGF primary ( count recovery preparative regimen ) secondary ( cytopenia engraftment occur ) . Patients autoimmune cytopenia auto antibody neutrophils platelet positive Coombs test respond immunosuppressive agent within 3 month initiation therapy eligible well . Persistent cytopenia require growth factor and/or blood product AND evidence hypocellular BM ( &lt; 25 % ) . Persistent cytopenia ( least 4 week period ) define presence TWO following : 1 . ANC &lt; 1.0x10^9/L without filgrastim support ANC value require recurrent support filgrastim ( administer least week ) . 2 . Plt &lt; 50x10^9/L 3 . Hb &lt; 8 PRBC transfusion dependent ( every 2 week ) reticulocyte count &lt; 40x10^9/L . This criteria persistent cytopenia hypocellular bone marrow apply patient autoimmune cytopenia , ONLY PGF patient Full donor myeloid chimerism . Patients T cell depletion transplant significant mixed T cell chimerism affect test marrow chimerism . In case , neutrophil chimerism use determine eligibility trial . Patients exclude neutrophils less 90 % donor cell ; high percentage host cell could due relapse impend relapse . Age : pediatrics adult patient . No age exclusion . Each patient must willing participate research subject must sign informed consent form . For infection end organ relate criterion ( time TCD boost administration ) see table protocol . Patients exclude trial time enrollment : Evidence relapse disease morphologic , cytogenetic molecular diagnostic tool . Hypersplenism document image study ( US CT ) Pregnant woman Patient underwent TCD boost without count recovery consider another TCD boost treat protocol .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>T-cell Depleted Hematopoietic Stem Cell</keyword>
	<keyword>Allogeneic Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>CliniMACS Cell Selection System</keyword>
	<keyword>14-228</keyword>
	<keyword>HSCT</keyword>
</DOC>